| Assessment Status | Rapid Review Complete |
| HTA ID | 23017 |
| Drug | Relugolix |
| Brand | Orgovyx® |
| Indication | Indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer. |
| Assessment Process | |
| Rapid review commissioned | 14/03/2023 |
| Rapid review completed | 31/03/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that relugolix not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations January 2024.
